Cofertility, a new Swedish-based fertility startup, is introducing an unconventional approach to egg freezing that aims to make fertility preservation more accessible to women while simultaneously addressing donor shortages in the assisted reproduction sector.
Under the company’s model, women can have their eggs frozen at no cost, provided they agree to donate half of the retrieved eggs to other individuals seeking fertility treatment. This arrangement represents a significant departure from traditional egg freezing services, where patients typically bear the full financial burden of the procedure.
Addressing Fertility Cost Barriers
Egg freezing remains an expensive procedure in most European markets, with costs often ranging from several thousand euros per cycle. The financial barrier has historically limited access to fertility preservation options, particularly for younger women who may wish to delay childbearing for career or personal reasons. Cofertility’s model attempts to democratize access to this technology by eliminating upfront costs for participating women.
The arrangement also tackles a persistent challenge within the fertility industry: the shortage of available egg donors. Many fertility clinics across Europe struggle to maintain adequate donor pools, resulting in extended waiting periods for patients who require donor eggs. By incentivizing donation through free freezing services, Cofertility positions itself to build a larger supply of eggs for patients in need.
Leadership and Vision
The company is led by Lauren Makler, a former executive at Uber who has transitioned into the healthtech sector. Makler’s background in a technology-driven company reflects Cofertility’s approach to modernizing fertility services through innovative business models rather than purely medical innovation.
European Context
The Swedish startup enters a fertility market increasingly characterized by technological innovation and new service models. Across Europe, the fertility sector has seen growing investment in digital health solutions and novel approaches to reproductive medicine. Countries including Sweden, Denmark, and Spain have established themselves as hubs for assisted reproduction services, driven by supportive regulatory frameworks and advanced medical infrastructure.
Cofertility’s launch reflects broader trends within the European healthtech ecosystem, where entrepreneurs are identifying gaps in healthcare accessibility and designing market-based solutions. The company’s model aligns with discussions about equity in fertility services, a topic gaining prominence as demographic patterns shift and more individuals seek to preserve reproductive options.
The startup’s approach also navigates complex ethical and regulatory considerations surrounding egg donation and compensation across European markets, where regulations vary significantly. As Cofertility scales, it will need to address jurisdiction-specific requirements regarding donor compensation and reproductive services.
The company’s emergence underscores the continued vitality of the European healthtech sector in developing alternative models for healthcare delivery, particularly in specialized fields where traditional approaches have historically limited access.